Posted on April 29th, 2019
Once the diagnosis of malignant mesothelioma is made by your doctor, further tests such as imaging and biopsy will be performed to check the extent to which cancer has spread in your body. This process known as staging helps doctors to start with an appropriate treatment plan and improve your prognosis.
Thus, mesothelioma staging is an essential part of the diagnostic procedure and a vital element in deriving an individualized treatment plan. It also plays a major role in deciding the patient's eligibility for undergoing tumor removal surgery. Mesothelioma is generally grouped into four stages, and stage 1 mesothelioma is localized, the malignancy has not spread beyond the point of origin, whereas stages 2 through 4 are considered to be advanced stages.
Patients with mesothelioma diagnosed at a less advanced stage tend to have a better chance of getting successfully treated and thus live longer. But, as mesothelioma has a latency period of almost 2-3 decades long and symptoms similar to that of other common ailments, most patients remain undiagnosed until they reach advanced stage 3 or 4. At these stages, patients will have worse prognosis due to the lack of curative treatment options.
Malignant pleural mesothelioma is the only type that has approved staging system at the present time. The Tumor, Nodes, and Metastasis (TNM) Staging System was first developed in the 1940s by a French physician, Pierre Denoix and in the early 1980s, A.P. Chahinian developed the first TNM staging system specific to mesothelioma. Currently, the American Joint Committee on Cancer (AJCC) approved the TNM staging system and is the most commonly used and often updated as per the new mesothelioma research that takes place. It is also referred to as the International Mesothelioma Interest Group (IMIG) Staging system. In this system, the factors such as the size of the tumor and extent, lymph node involvement, and metastasis are taken into account to classify the pleural mesothelioma stage.
The TNM staging system describes cancer in detail. The letter T stands for the tumor and explains the size and extent of the primary tumor, the letter N denotes the number of lymph nodes involved, and the letter M refers to the metastasis or distant spread of the tumor to other parts of the body. In the TNM system, each letter is followed by a number that provides more details about cancer staged, and here's what these mean:
The evaluation of all the above factors places the patient in one of the following 4 stages. In January 2018, the TNM system was updated to include subcategories such as stage 1A and stage 1B.
Any T, Any N, M1: By this stage, mesothelioma may or may not have spread into places near the main mass (any T). It may or may not have spread to lymph nodes (any N) but has spread to distant places such as the bones, liver, lungs, abdominal lining or lining of the lungs on the other side of the chest (M1).
First and foremost, the physicians who follow the TNM staging system can group your diagnosis into categories, which helps in determining the appropriate stage. Accurate staging is important as it determines your eligibility for certain treatment procedures. In addition, it helps:
At Environmental Litigation Group, P.C., we do have a medical research team that follows the TNM staging of cancer to ensure you get the most accurate diagnosis, and regardless of the stage of mesothelioma you have been diagnosed with, you are entitled to receive financial compensation.